Characterization of blockade antibody responses in GII.2.1976 snow mountain virus-infected subjects

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 829-837

  Swanstrom, Jesica ^a   Lindesmith, Lisa C ^a   Donaldson, Eric F ^a   Yount, Boyd ^a   Baric, Ralph S ^a,b  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN; REPLICON; SNOW MOUNTAIN GASTROENTERITIS VIRUS; SNOW MOUNTAIN VIRUS INFECTION; TRANSMISSION ELECTRON MICROSCOPY; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS SHEDDING; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CROSS REACTIONS; EPITOPES; GENOTYPE; HUMANS; MICE; NEUTRALIZATION TESTS; NOROVIRUS;

EID: 84891700334     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02793-13     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention. 2011. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm. Rep. 60:1-18. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6003a1.htm.
2. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-1231. http://dx.doi.org/10.3201/eid1408.071114.
3. Centers for Disease Control and Prevention. 2007. Norovirus activity-United States, 2006-2007. MMWR Morb. Mortal. Wkly. Rep. 56:842-846. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5633a2.htm.
4. Harris JP, Edmunds WJ, Pebody R, Brown DW, Lopman BA. 2008. Deaths from norovirus among the elderly, England and Wales. Emerg. Infect. Dis. 14:1546-1552. http://dx.doi.org/10.3201/eid1410.080188.
5. Okada M, Tanaka T, Oseto M, Takeda N, Shinozaki K. 2006. Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch. Virol. 151:1635-1641. http://dx.doi.org/10.1007/s00705-006-0739-6.
6. Hall AJ. 2012. Noroviruses: the perfect human pathogens? J. Infect. Dis. 205:1622-1624. http://dx.doi.org/10.1093/infdis/jis251.
7. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625. http://dx.doi.org/10.3201/eid0505.990502.
8. Capizzi T, Makari-Judson G, Steingart R, Mertens WC. 2011. Chronic diarrhea associated with persistent norovirus excretion in patients with chronic lymphocytic leukemia: report of two cases. BMC Infect. Dis. 11:131. http://dx.doi.org/10.1186/1471-2334-11-131.
9. Lambregts MM, Alleman MA, Ruys GJ, Groeneveld PH. 2010. Chronic norovirus infection in an immunocompromised patient. Ned. Tijdschr. Geneeskd. 154:A1067. (In Dutch.)
10. Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, Muller NJ, Fehr T. 2010. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin. Infect. Dis. 51:307-314. http://dx.doi.org/10.1086/653939.
11. Glass PJ, White LJ, Ball JM, Leparc-Goffart I, Hardy ME, Estes MK. 2000. Norwalk virus open reading frame 3 encodes a minor structural protein. J. Virol. 74:6581-6591. http://dx.doi.org/10.1128/JVI.74.14.6581-6591.2000.
12. Zheng D-P, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. 2006. Norovirus classification and proposed strain nomenclature. Virology 346:312-323. http://dx.doi.org/10.1016/j.virol.2005.11.015.
13. Kageyama T, Shinohara M, Uchida K, Fukushi S, Hoshino FB, Kojima S, Takai R, Oka T, Takeda N, Katayama K. 2004. Coexistence of multiple genotypes, including newly identified genotypes, in outbreaks of gastroenteritis due to norovirus in Japan. J. Clin. Microbiol. 42:2988-2995. http://dx.doi.org/10.1128/JCM.42.7.2988-2995.2004.
14. Chen R, Neill JD, Estes MK, Prasad BVV. 2006. X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc. Natl. Acad. Sci. U. S. A. 103:8048-8053. http://dx.doi.org/10.1073/pnas.0600421103.
15. Choi J-M, Hutson AM, Estes MK, Prasad BVV. 2008. Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc. Natl. Acad. Sci. U. S. A. 105:9175-9180. http://dx.doi.org/10.1073/pnas.0803275105.
16. Clarke IN, Lambden PR. 2000. Organization and expression of calicivirus genes J. Infect. Dis. 181:S309-S316. http://dx.doi.org/10.1086/315575.
17. Prasad BVV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290. http://dx.doi.org/10.1126/science.286.5438.287.
18. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. 2012. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J. Virol. 86:1214-1226. http://dx.doi.org/10.1128/JVI.06189-11.
19. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2010. Viral shape-shifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8:231-241. http://dx.doi.org/10.1038/nrmicro2296.
20. Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS. 2012. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 8:e1002705. http://dx.doi.org/10.1371/journal.ppat.1002705.
21. Lindesmith LC, Costantini V, Swanstrom J, Debbink K, Donaldson EF, Vinje J, Baric RS. 2013. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J. Virol. 87:2803-2813. http://dx.doi.org/10.1128/JVI.03106-12.
22. Lindesmith LC, Donaldson EF, Baric RS. 2011. Norovirus GII.4 strain antigenic variation. J. Virol. 85:231-242. http://dx.doi.org/10.1128/JVI.01364-10.
23. Siebenga JJ, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen RJ, Koopmans M. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81:9932-9941. http://dx.doi.org/10.1128/JVI.00674-07.
24. Iritani N, Vennema H, Siebenga JJ, Siezen RJ, Renckens B, Seto Y, Kaida A, Koopmans M. 2008. Genetic analysis of the capsid gene of genotype GII.2 noroviruses. J. Virol. 82:7336-7345. http://dx.doi.org/10.1128/JVI.02371-07.
25. Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinje J. 2009. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J. Virol. 83:5363-5374. http://dx.doi.org/10.1128/JVI.02518-08.
26. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225:190-211. http://dx.doi.org/10.1111/j.1600-065X.2008.00680.x.
27. Hutson AM, Atmar RL, Graham DY, Estes MK. 2002. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185:1335-1337. http://dx.doi.org/10.1086/339883.
28. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9:548-553. http://dx.doi.org/10.1038/nm860.
29. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, Clement M, Cailleau-Thomas A, Ruiz-Palacois G, Huang P, Jiang X, Le Pendu J. 2002. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122:1967-1977. http://dx.doi.org/10.1053/gast.2002.33661.
30. Moe CL, Sair A, Lindesmith L, Estes MK, Jaykus LA. 2004. Diagnosis of Norwalk virus infection by indirect enzyme immunoassay detection of salivary antibodies to recombinant Norwalk virus antigen. Clin. Diagn. Lab. Immunol. 11:1028-1034. http://dx.doi.org/10.1128/CDLI.11.6.1028-1034.2004.
31. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365:2178-2187. http://dx.doi.org/10.1056/NEJMoa1101245.
32. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. 2010. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202:1212-1218. http://dx.doi.org/10.1086/656364.
33. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. 2002. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76:12335-12343. http://dx.doi.org/10.1128/JVI.76.23.12335-12343.2002.
34. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5:e31. http://dx.doi.org/10.1371/journal.pmed.0050031.
35. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, Weber DJ, Baric RS. 2010. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84:1800-1815. http://dx.doi.org/10.1128/JVI.02179-09.
36. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, Moe CL, Baric RS. 2006. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24:5220-5234. http://dx.doi.org/10.1016/j.vaccine.2006.03.080.
37. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. 2005. Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79:2900-2909. http://dx.doi.org/10.1128/JVI.79.5.2900-2909.2005.
38. Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X. 2005. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 79:6714-6722. http://dx.doi.org/10.1128/JVI.79.11.6714-6722.2005.
39. Baric RS, Yount B, Lindesmith L, Harrington PR, Greene SR, Tseng F-C, Davis N, Johnston RE, Klapper DG, Moe CL. 2002. Expression and self-assembly of Norwalk virus capsid protein from Venezuelan equine encephalitis virus replicons. J. Virol. 76:3023-3030. http://dx.doi.org/10.1128/JVI.76.6.3023-3030.2002.
40. Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS. 2002. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J. Virol. 76:730-742. http://dx.doi.org/10.1128/JVI.76.2.730-742.2002.
41. Lindesmith LC, Debbink K, Swanstrom J, Vinje J, Costantini V, Baric RS, Donaldson EF. 2012. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J. Virol. 86:873-883. http://dx.doi.org/10.1128/JVI.06200-11.
42. Hansman GS, Taylor DW, McLellan JS, Smith TJ, Georgiev I, Tame JR, Park SY, Yamazaki M, Gondaira F, Miki M, Katayama K, Murata K, Kwong PD. 2012. Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J. Virol. 86:3635-3646. http://dx.doi.org/10.1128/JVI.06868-11.
43. Tan M, Jiang X. 2010. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog. 6:e1000983. http://dx.doi.org/10.1371/journal.ppat.1000983.
44. Tian P, Yang D, Jiang X, Zhong W, Cannon JL, Burkhardt W, III, Woods JW, Hartman G, Lindesmith L, Baric RS, Mandrell R. 2010. Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J. Appl. Microbiol. 109:1753-1762. http://dx.doi.org/10.1111/j.1365-2672.2010.04812.x.
45. Debbink K, Lindesmith LC, Donaldson EF, Costantini V, Beltramello M, Corti D, Swanstrom J, Lanzavecchia A, Vinje J, Baric RS. 2013. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J. Infect. Dis. 208:1877-1887. http://dx.doi.org/10.1093/infdis/jit370.
46. Hansman GS, Natori K, Shirato-Horikoshi H, Ogawa S, Oka T, Katayama K, Tanaka T, Miyoshi T, Sakae K, Kobayashi S, Shinohara M, Uchida K, Sakurai N, Shinozaki K, Okada M, Seto Y, Kamata K, Nagata N, Tanaka K, Miyamura T, Takeda N. 2006. Genetic and antigenic diversity among noroviruses. J. Gen. Virol. 87:909-919. http://dx.doi.org/10.1099/vir.0.81532-0.
47. Hansman GS, Shahzad-ul-Hussan McLellan JS, Chuang G-Y, Georgiev I, Shimoike T, Katayama K, Bewley CA, Kwong PD. 2012. Structural basis for norovirus inhibition and fucose mimicry by citrate. J. Virol. 86:284-292. http://dx.doi.org/10.1128/JVI.05909-11.
48. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. 2009. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83:3212-3227. http://dx.doi.org/10.1128/JVI.01650-08.
49. Borrego B, Camarero JA, Mateu MG, Domingo E. 1995. A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Viral Immunol. 8:11-18. http://dx.doi.org/10.1089/vim.1995.8.11.
50. Lochridge VP, Hardy ME. 2007. A single-amino-acid substitution in the P2 domain of VP1 of murine norovirus is sufficient for escape from antibody neutralization. J. Virol. 81:12316-12322. http://dx.doi.org/10.1128/JVI.01254-07.
51. Petitdemange C, Achour A, Dispinseri S, Malet I, Sennepin A, Ho Tsong Fang R, Crouzet J, Marcelin AG, Calvez V, Scarlatti G, Debre P, Vieillard V. 2013. A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. Clin. Infect. Dis. 57:745-755. http://dx.doi.org/10.1093/cid/cit335.
52. Parra GI, Azure J, Fischer R, Bok K, Sandoval-Jaime C, Sosnovtsev SV, Sander P, Green KY. 2013. Identification of a broadly cross-reactive epitope in the inner shell of the norovirus capsid. PLoS One 8:e67592. http://dx.doi.org/10.1371/journal.pone.0067592.